Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly logo
Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly Updated August 04, 2026

SLIT Tablets (Ages 5–65): First‑Dose Supervision, Epinephrine, Start Windows

Introduction

Sublingual immunotherapy (SLIT) tablets are FDA‑approved allergy immunotherapy options for environmental allergens. As of February 28, 2025, all four U.S. SLIT tablets (Odactra, Grastek, Ragwitek, Oralair) carry boxed warnings for anaphylaxis, require first‑dose supervision with at least 30 minutes of observation, and require prescribing an epinephrine auto‑injector for home use. They are approved for patients 5 through 65 years of age (see brand specifics below). These are not rescue medicines. They modify disease over time when used exactly per label.

What’s common to all U.S. SLIT tablets

  • Boxed warning: risk of severe allergic reactions (including anaphylaxis and severe laryngopharyngeal edema).

  • First dose in a medical facility; observe for ≥30 minutes. Subsequent dosing is at home.

  • Epinephrine: clinicians must prescribe an auto‑injector and train users; patients are instructed to seek immediate medical care after use.

  • Key contraindications (across labels): severe/unstable/uncontrolled asthma; history of severe systemic reaction to SLIT; history of severe local SLIT reaction; history of eosinophilic esophagitis; hypersensitivity to tablet excipients. Use caution in patients on beta‑blockers (may be less responsive to epinephrine).

  • Administration notes: place tablet under the tongue; avoid swallowing for about 1 minute; no food or drink for 5 minutes after dosing; wash hands after handling. Children dose under adult supervision.

  • Professional society guidance mirrors labels: first dose in clinic with 30‑minute observation; prescribe epinephrine; provide education on pauses (e.g., mouth surgery, oral ulcers) and missed doses.

Start‑by windows (pre‑season timing)

  • Grastek (Timothy grass): start at least 12 weeks before the expected onset of grass season; continue through the season.

  • Oralair (5‑grass mix): start about 4 months before grass season; continue through the season.

  • Ragwitek (short ragweed): start at least 12 weeks before ragweed season; continue through the season.

  • Odactra (house dust mite): perennial allergen; start any time of year; dose daily year‑round. (On Feb 28, 2025, FDA expanded Odactra’s indication to ages 5–11, making it 5–65.)

Quick comparison (label‑accurate)

Tablet Allergen FDA‑approved ages When to start First dose & observation Epinephrine at home
Odactra House dust mite (D. farinae, D. pteronyssinus) 5–65 Anytime (year‑round) In clinic; observe ≥30 min Required
Grastek Timothy grass (cross‑reactive grasses) 5–65 ≥12 weeks before grass season In clinic; observe ≥30 min Required
Oralair 5‑grass mix (sweet vernal, orchard, perennial rye, Timothy, Kentucky blue) 5–65 ~4 months before grass season In clinic; observe ≥30 min Required
Ragwitek Short ragweed 5–65 ≥12 weeks before ragweed season In clinic; observe ≥30 min Required

Regulatory sources: Odactra PI/FDA page; Grastek PI; Oralair PI; Ragwitek PI.

Brand‑by‑brand essentials

Odactra (house dust mite; daily, year‑round)

  • Indication & ages: HDM‑induced allergic rhinitis with/without conjunctivitis; 5–65 years.

  • Safety: boxed warning; first dose in clinic with ≥30‑minute observation; prescribe epinephrine. Contraindicated in severe/unstable/uncontrolled asthma; prior severe SLIT reactions; EoE; or excipient hypersensitivity.

  • Practical: tablet dissolves quickly under the tongue; avoid food/drink for 5 minutes.

Grastek (Timothy grass)

  • Indication & ages: grass‑pollen–induced allergic rhinitis with/without conjunctivitis; 5–65 years.

  • Start window: initiate ≥12 weeks before grass season; continue through season. For sustained effect one season after stopping, a daily 3‑year course may be used (per label).

  • Safety: boxed warning; first dose in clinic with ≥30‑minute observation; prescribe epinephrine; standard SLIT contraindications apply.

Oralair (5‑grass mix)

  • Indication & ages: grass‑pollen–induced allergic rhinitis with/without conjunctivitis; 5–65 years.

  • Start window: start about 4 months before grass season; continue through the season.

  • Safety: boxed warning; first dose in clinic with ≥30‑minute observation; prescribe epinephrine; standard SLIT contraindications apply. Pediatric starter‑pack titration is specified in the label.

Ragwitek (short ragweed)

  • Indication & ages: ragweed‑pollen–induced allergic rhinitis with/without conjunctivitis; 5–65 years.

  • Start window: initiate ≥12 weeks before ragweed season; continue through the season.

  • Safety: boxed warning; first dose in clinic with ≥30‑minute observation; prescribe epinephrine; standard SLIT contraindications apply.

Clinical and society guidance (context)

  • AAAAI/ACAAI patient and guideline resources reiterate: first dose in clinic with 30‑minute observation; provide epinephrine and training; tablets are FDA‑approved while SLIT drops are not FDA‑approved in the U.S.

Practical checklist for families (ages 5–65)

1) Book the first‑dose visit (≥30 minutes observed). 2) Fill epinephrine and review when/how to use it. 3) Plan daily dosing at home: dry hands, under‑tongue placement, avoid swallowing for ~1 minute, no food/drink for 5 minutes. 4) Pause dosing for active oral wounds/inflammation per label; call your clinician after severe reactions or if asthma control worsens. 5) Expect disease‑modifying benefit over seasons, not instant relief.

FAQs

  • Do I have to start before the season? Yes—seasonal tablets specify pre‑season starts (Grastek and Ragwitek ≥12 weeks; Oralair ~4 months). Starting in‑season has not been established for safety/efficacy in the labels. Odactra (dust mite) can be started any time of year.

  • Do I need an epinephrine auto‑injector? Yes. All SLIT tablet labels require prescribing epinephrine and patient training. Carry it at all times while on therapy.

  • Who should not take SLIT tablets? Anyone with severe/unstable/uncontrolled asthma; history of severe systemic or severe local SLIT reaction; history of eosinophilic esophagitis; or hypersensitivity to tablet excipients. Discuss beta‑blocker or MAOI use with your clinician.

  • Are SLIT drops FDA‑approved? No. In the U.S., only SLIT tablets (dust mite, selected grasses, ragweed) are FDA‑approved; drops are off‑label.

  • What are the approved ages? All four tablets are currently FDA‑approved for ages 5–65 (Odactra age expansion to 5–11 approved on Feb 28, 2025). Always verify the specific product’s label at prescribing.

Notes for clinicians

  • Labels specify education on treatment interruptions; some products allow up to ~7 days missed in trials. Follow product‑specific instructions.

  • For Grastek, a continuous 3‑year course can confer sustained efficacy for the following season per label. Oralair and Ragwitek labels specify pre‑seasonal/seasonal courses. Tailor by patient, region, and pollen forecasts.

Last label/access dates: Odactra (updated 02/2025; FDA page accessed Oct 28, 2025); Grastek (accessed Oct 28, 2025); Ragwitek (accessed Oct 28, 2025); Oralair (accessed Oct 28, 2025); AAAAI/ACAAI pages (accessed Oct 28, 2025).